65,437 trials
Lymphoma, Non-Hodgkin
Primary: Safety: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 1; 0 Participants
Substance-Related Disorders · Mental Health
Primary: Trajectory of Depression of Participants — 40; 28; 18; 27 Participants — p=<.05
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Assessment and Severity Index (PASI) Score at Week 24 — 23.1; 23.4; 16.5; 17.1 units on a scale
Onychomycosis
Primary: Number of Patients in Each Treatment Group With a Complete Therapeutic Cure — 1; 0; 1 Participants — p=0.4615
Contraceptive Behavior
Primary: Appointment Adherence (Efficacy) — 34; 28 participants — p=<.05
Headache, Migraine
Primary: Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol — 132; 143 pg/mL
Moderate to Severe Plaque-type Psoriasis
Primary: Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68 — 49.8; 25.4; 74.3; 64.7 Cummulative rate — p=<0.0001
Respiratory Depression
Primary: Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported. — 0 Participants
Leucocytosis
Primary: AUC (0-48 Hours) — 168603.588; 181152; 411826.811; 427355.99 picogram per ml / hour
Postoperative Nausea and Vomiting
Primary: Number of Participants With Complete Response (Success of Initial PONV Treatment) — 80; 96; 67 Participants — p=0.003
Metastatic Castration-resistant Prostate Cancer
Primary: Progression-free Survival (PFS) — 1 Participants
Advanced Malignant Solid Tumors
Primary: Dose Limiting Toxicity (DLT) - Percentage of Participants With DLT Events — 1 Participants
Postoperative Nausea and Vomiting
Primary: Complete Response (Success of Initial PONV Treatment) — 60; 59; 39 Participants — p=0.016
Nicotine Dependence
Primary: Cigarettes Smoked Per Day — 14.19; 14.23; 7.67; 7.76 Cigarettes per day
Prostate Cancer
Primary: Overall Survival — 15.3; 17.1 months — p=0.12085